MedTrace Logo

A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis

NCT03144687 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2022-06-16

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy and safety of itacitinib combined with low-dose ruxolitinib or itacitinib alone in participants with myelofibrosis (MF).

Conditions

  • MPN (Myeloproliferative Neoplasms)

Interventions

DRUG

Itacitinib

Itacitinib self-administered orally once daily .

DRUG

Ruxolitinib

Ruxolitinib self-administered orally at the stable dose of \< 20 mg daily established before entering the study.

Sponsors & Collaborators

Principal Investigators

  • Peter Langmuir · Incyte Corporation

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-26
Primary Completion
2020-03-14
Completion
2021-06-01
FDA Drug
Yes

Countries

  • United States
  • Austria
  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03144687 on ClinicalTrials.gov